Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation
Authors:
- Tetsuji MiuraTMTetsuji Miura
- Nobuyuki UraNUNobuyuki Ura
- Takashi OgawaTOTakashi Ogawa
- Katsuo SuzukiKSKatsuo Suzuki
- Kazuaki ShimamotoKSKazuaki Shimamoto
- Osamu IimuraOIOsamu Iimura
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit heartsJournal of Molecular and Cellular Cardiology, 1995
- Repeated measurements and multiple comparisons in cardiovascular researchCardiovascular Research, 1994
- Infarct size limitation by preconditioning: its phenomenological features and the key role of adenosineCardiovascular Research, 1993
- Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioningCardiovascular Research, 1992
- Role of Kallikrein-Kinin System in the Hypotensive Mechanisms of Converting Enzyme Inhibitors in Essential HypertensionJournal of Cardiovascular Pharmacology, 1989
- The mechanism of the hypotensive effect of captopril (converting enzyme inhibitor) with special reference to the kallikrein-kinin and renin-angiotensin systems.Japanese Journal of Medicine, 1986
- Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarctionAmerican Heart Journal, 1985
- Effects of Captopril on Limiting Infarct Size in Conscious DogsJournal of Cardiovascular Pharmacology, 1984
- Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size.Circulation, 1982
- Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor.Circulation, 1982